Insights into the association of ACEIs/ARBs use and COVID-19 prognosis: a multistate modelling study of nationwide hospital surveillance data from Belgium.

ABSTRACT:

Objectives

The widespread use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) by patients with chronic conditions raised early concerns on the potential exacerbation of COVID-19 severity and fatality. Previous studies addressing this question have used standard methods that may lead to biased estimates when analysing hospital data because of the presence of competing events and event-related dependency. We investigated the association of ACEIs/ARBs' use with COVID-19 disease outcomes using time-to-event data in a multistate setting to account for competing events and minimise bias.

Setting

Nationwide surveillance data from 119 Belgian hospitals.

Participants

Medical records of 10 866 patients hospitalised from 14 March 2020

SUBMITTER: Penalvo JL 

PROVIDER: S-EPMC8449849 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature